CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Jennifer R. Brown; Peter Hillmen; Barbara Eichhorst; Nicole Lamanna; Susan O'Brien; Constantine S. Tam; Lugui Qiu; Maciej Kazmierczak; Keshu Zhou; Martin Šimkovič; Jiri Mayer; Amanda Gillespie-Twardy; Mazyar Shadman; Alessandra Ferrajoli; Peter S. Ganly; Robert Weinkove; Tommi Salmi; Kenneth Wu; William Novotny; Wojciech Jurczak

doi:10.1016/S2152-2650(22)01324-6

$CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)$

Journal article

Peer reviewed

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Jennifer R. Brown, Peter Hillmen, Barbara Eichhorst, Nicole Lamanna, Susan O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, …

Clinical lymphoma, myeloma and leukemia, Vol.22, p.S266

10/2022

DOI: https://doi.org/10.1016/S2152-2650(22)01324-6

Handle:

https://hdl.handle.net/10523/21986

Metrics

9 Record Views

See more details

Details

Record Identifier: 9926495525701891
Title: CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Creators: Jennifer R. Brown
Peter Hillmen
Barbara Eichhorst
Nicole Lamanna
Susan O'Brien
Constantine S. Tam
Lugui Qiu
Maciej Kazmierczak
Keshu Zhou
Martin Šimkovič
Jiri Mayer
Amanda Gillespie-Twardy
Mazyar Shadman
Alessandra Ferrajoli
Peter S. Ganly
Robert Weinkove
Tommi Salmi
Kenneth Wu
William Novotny
Wojciech Jurczak
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, p.S266
Academic Unit: Medicine (DSM); Pathology and Molecular Medicine (UOC)
Date published ; e-published: 10/2022
Language: English
Resource Type ; Subtype: Journal article

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Related links

Metrics

Details